Nimbly engaging health care regulators, business-focused solutions

Edward Rickert is a pharmacist and attorney who represents health care providers and drug and medical device manufacturers. With deep knowledge of the pharmacy and health care industries, Ed advises in three key areas:

• Health care regulatory compliance
• Health care litigation
• Controlled Substances Act (CSA) and Drug Enforcement Administration (DEA) compliance

Clients appreciate that with Ed there is no learning curve. He understands not only the evolving legal and regulatory landscape facing health care entities and professionals, but their operations, business models and the rapid changes in the industry owing to technology and other dynamics. They also like his practical, business-focused legal advice, his responsive, collaborative approach and his ability to engage regulators — often avoiding the formal, adversarial processes that cost time and money.

Admitted in Illinois. Not admitted in Florida.

Bar Admissions

• Illinois

Education

• Chicago-Kent College of Law - Illinois Institute of Technology (J.D., with honors, 1988)

• University of Iowa (B.S., 1983)
  • Pharmacy

• "2011 Legislative Update"
• "340B Discount Drug Program: Updates and Changes Affecting Contract Pharmacies"
• "A Malpractice Primer for Pharmacists"
• "Bioterrorism Preparedness Training for Pharmacists and Nurses – Special Populations: Legal and Regulatory Issues"
• "Board of Pharmacy Boot Camp: Avoiding Unwanted Attention"
• "Compounding Pharmacy Perspectives"
• "Compounding versus Manufacturing and Other Light- Hearted Legal Issues in Illinois: Where We Are and Where We Are Headed"
• "Constitutional Challenges to Pharmacy Statutes and Regulations"
• "DEA Update"
• "Defending Drug Charges: Drug Abuse and Malprescribing, American Society of Interventional Pain Physicians"
• "Drug Diversion: Is it Legitimate?"
• "Emerging Considerations for Specialty Pharmacies"
• "For What It’s Worth: Controlled Substance Act Compliance in the Post-Prescription Opioid Crisis and Post-COVID World"
• "Hot Topics in Pharmacy Law"
• "Hot Topics in Pharmacy Law: The Good, the Bad and the Ugly"
• "Illinois Controlled Substances Act Update"
• "Illinois Law Update, 2011 Continuing Education Fall Summit"
• "Improving Access in Healthcare through the Use of Telemedicine, Telepharmacy and Telenursing"
• "Is it Legitimate? Understanding the Pharmacist's Corresponding Responsibility under the Controlled Substances Act"
• "Legal and Regulatory Issues in Self-Care Pharmacy Practice"
• "Moderated Panel of State Board of Pharmacy Counsel"
• "New Technologies, Old Concerns"
• "Opioid Crisis—Top Things to Know"
• "Oregon Adds Suspicious Order Reporting to Wholesale Distributor Requirements"
• "Pharmacy Law - Examination and Board Review"
• "Pharmacy Law—Examination and Board Review: Federal Chapter"
• "Pharmacy Law—Examination and Board Review: Illinois Chapter"
• "Pharmacy Law—Examination and Board Review: Wisconsin Chapter"
• "Pharmacy Malpractice: The View From The Courts"
• "Pharmacy Practice Update 2012"
• "Practice Issues"
• "Protecting Provider Records from Discovery – Patient Safety Organizations (PSO) and Other Programs"
• "Reclaiming Authority over Professional Standards for Controlled Substance Dispensing: Is the DEA Always Right? Or, Can Pharmacists Develop Less Restrictive and More Effective Rules to Reduce Controlled Substance Diversion?"
• "State Law Overview"
• "Telepharmacy Best Practices for Pharmacists and Providers"
• "The Impact of the Dobbs Decision on Pharmacy"
• "The Last Line of Defense: Pharmacists' Corresponding Responsibility"
• "Treating 'Pain Management' Patients Effectively"
• "Trends in the Regulation of Automation, American Society for Pharmacy Law"
• "Unique Delivery Methods"
• Are You Interested in the FDA's Guidance on Outsourcing Facilities? Your Time to Comment Is Ending Soon!
• Brace Yourself: DEA’s Final Rule on Quotas Squeezes Inventory Levels and Signals Further Supply Restrictions
• Changes to Pharmacy Rules Governing Automated Storage and Delivery Systems Due to COVID-19
• Chicago Commissioner of Public Health Publishes Proposed Pharmaceutical Representative Licensing Rules
• City of Chicago Imposes Licensing Requirement Upon Pharmaceutical Representatives
• DEA Issues Final Order Increasing APQs for Certain Controlled Substances
• DEA Temporarily Removes the 'Five Percent Rule'
• DEA’s “X” Waiver Eliminated by Congress
• Final Definitions and Considerations for Trading Partners to Prepare for DSCSA Implementation
• Florida Board of Pharmacy Proposes Amendments to Rule on Technician to Pharmacist Ratio
• Georgia Board of Pharmacy Continues to Review Licensure Requirements for Pharmacists
• HHS Recommends ‘Replanting’ Marijuana in Schedule III
• High Court Rules “State of Mind” Relevant in Prosecuting Prescribers under the Controlled Substance Act
• Hot Off the Press: Mississippi Board of Pharmacy Files Proposed Rule on Shared Pharmacy Services
• Illinois Proposes Licensure for Pharmacists-in-Charge of Nonresident Pharmacies
• Kansas Now Requires Non-resident Pharmacies to Designate a Kansas-licensed PIC
• Kentucky Withdraws Controversial Non-Resident Pharmacist License Regulation
• Key Takeaways from Newly Signed Bill Aimed to Combat Opioid Crisis
• Key Takeaways of the DEA's 2019 National Drug Threat Assessment
• Navigating Abortion Restrictions Post Dobbs: Considerations for Pharmacy Providers
• Nevada Seeks Formal AG Opinion Regarding Licensure for Out-of-State Pharmacists
• Nevada to Require Out-of-State Pharmacists that Dispense or Compound for Nevada Patients to Hold a Nevada Pharmacist’s License
• New FDA Draft Compounding Guidance for Pharmacies, Hospitals, and Outsourcing Facilities
• New Wisconsin Law Regulates PBM and Other Stakeholders Involved in Drug Pricing
• New York Abandons Proposed Rule Addressing Central Fill Arrangements, Will Seek Statutory Change
• OIG's Final Rule on Revisions to Civil Monetary Penalty Rules Regarding Beneficiary Inducements
• Oregon Adds Suspicious Order Reporting to Wholesale Distributor Requirements
• Protect Your CSOS Credentials…Or Else.
• Revised Amendments to Texas Central Fill Rule Address Concerns for Misinterpretation
• The OIG Green Lights Brand Manufacturer's Discount Drug Program
• T​he 340B Program Mega Guidance: Muddying the Water for All Stakeholders

Seminar

• 2015 Pharmacy Law Symposium
• 2018 American Society for Pharmacy Law Fall Meeting
• 2018 Pharmacy Law Symposium
• 2019 Pharmacy Law Symposium
• 2021 Pharmacy Law Symposium
• 2022 Pharmacy Law Symposium
• 2023 Pharmacy Law Symposium
• 2024 Pharmacy Law Symposium
• How the Uptick in Opioid Litigation is Affecting the Industry: Key Takeaways from the MDLs
• Infusion Pharmacy Services: Regulatory Considerations Impacting the Business Model
• Opioid Crisis — Top Things to Know
• Telepharmacy Best Practices for Pharmacists and Providers
• Virtual "Mini" Pharmacy Law Symposium